Roivant Reports Strong Pipeline Progress and $2.25B Moderna Settlement
Event summary
- IMVT-1402 showed 72.7% ACR20 response rate in difficult-to-treat rheumatoid arthritis trial.
- Brepocitinib received Breakthrough Therapy Designation for cutaneous sarcoidosis.
- Roivant reached a $2.25B settlement with Moderna, ending all patent litigation.
- Roivant reported $4.3B in cash and marketable securities as of March 31, 2026.
- Commercial launch of brepocitinib in dermatomyositis expected by September 2026.
The big picture
Roivant's strong financial position and pipeline progress underscore its strategic shift towards becoming a fully integrated biopharmaceutical company. The $2.25B settlement with Moderna not only resolves long-standing litigation but also provides significant financial flexibility. The company's focus on advancing multiple clinical candidates positions it to capitalize on growing demand for innovative therapies in autoimmune and inflammatory diseases.
What we're watching
- Clinical Milestones
- Whether IMVT-1402 can maintain its strong response rates in later-stage trials and whether brepocitinib can secure additional regulatory approvals.
- Financial Strategy
- How Roivant will allocate its $4.3B cash position to support ongoing clinical development and potential acquisitions.
- Regulatory Dynamics
- The pace at which brepocitinib and other Roivant candidates advance through the FDA approval process.
Related topics